These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36661315)

  • 1. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
    Kim WS; Fukuhara N; Yoon DH; Yamamoto K; Uchida T; Negoro E; Izutsu K; Terui Y; Nakajima H; Ando K; Suehiro Y; Kang HJ; Ko PS; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Tobinai K
    Blood Adv; 2023 Sep; 7(17):4903-4912. PubMed ID: 36661315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological profile and clinical study results of darinaparsin (DARVIAS
    Yao K; Sonehara Y; Nagahama F
    Nihon Yakurigaku Zasshi; 2023; 158(5):408-418. PubMed ID: 37673618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
    Ogura M; Kim WS; Uchida T; Uike N; Suehiro Y; Ishizawa K; Nagai H; Nagahama F; Sonehara Y; Tobinai K
    Jpn J Clin Oncol; 2021 Feb; 51(2):218-227. PubMed ID: 33051668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.
    Negoro E; Yamauchi T; Fukuhara N; Yamamoto K; Uchida T; Izutsu K; Maruyama D; Terui Y; Nakajima H; Ando K; Suehiro Y; Choi I; Kanemura N; Nakamura N; Yamamoto G; Maeda Y; Shibayama H; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Kim WS; Tobinai K
    J Clin Exp Hematop; 2023; 63(2):108-120. PubMed ID: 37380467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
    Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
    Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma.
    Witzig T; Sokol L; Kim WS; de la Cruz Vicente F; Martín García-Sancho A; Advani R; Roncero Vidal JM; de Oña Navarrete R; Marín-Niebla A; Rodriguez Izquierdo A; Terol MJ; Domingo-Domenech E; Saunders A; Bendris N; Mackey J; Leoni M; Foss F
    Blood Adv; 2024 Sep; 8(17):4581-4592. PubMed ID: 38991123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
    Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
    Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
    Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
    Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.
    Liu Y; Song Y; Zuo S; Zhang X; Liu H; Wang J; Wang J; Tang Y; Zheng W; Ying Z; Ping L; Zhang C; Wu M; Zhu J; Xie Y
    Front Immunol; 2023; 14():1128172. PubMed ID: 37081867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
    Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
    Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.